Clover Health Investments, Corp. (NASDAQ:CLOV) Director Carladenise Armbrister Edwards Sells 200,000 Shares of Stock

Clover Health Investments, Corp. (NASDAQ:CLOV) Director Carladenise Armbrister Edwards sold 200,000 shares of the company’s stock in a transaction on Friday, March 7th. The shares were sold at an average price of $3.61, for a total value of $722,000.00. Following the completion of the transaction, the director now directly owns 273,227 shares in the company, valued at $986,349.47. This represents a 42.26 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Clover Health Investments Stock Down 0.9 %

Shares of NASDAQ:CLOV opened at $3.36 on Wednesday. Clover Health Investments, Corp. has a 12-month low of $0.61 and a 12-month high of $4.87. The company has a market cap of $1.72 billion, a P/E ratio of -16.80 and a beta of 2.00. The company’s fifty day moving average is $4.09 and its two-hundred day moving average is $3.62.

Hedge Funds Weigh In On Clover Health Investments

Hedge funds have recently modified their holdings of the stock. Concurrent Investment Advisors LLC acquired a new position in shares of Clover Health Investments in the third quarter worth $28,000. Sigma Planning Corp bought a new stake in Clover Health Investments during the third quarter valued at about $29,000. Parallax Volatility Advisers L.P. bought a new stake in Clover Health Investments during the third quarter valued at about $38,000. Triumph Capital Management bought a new stake in Clover Health Investments during the fourth quarter valued at about $45,000. Finally, KBC Group NV bought a new stake in shares of Clover Health Investments in the third quarter valued at about $53,000. 19.77% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on CLOV shares. Canaccord Genuity Group upped their price target on Clover Health Investments from $4.20 to $4.50 and gave the company a “buy” rating in a report on Monday, March 3rd. Craig Hallum initiated coverage on shares of Clover Health Investments in a research note on Tuesday, December 17th. They set a “buy” rating and a $6.00 target price on the stock.

About Clover Health Investments

Clover Health Investments, Corp. provides medicare advantage plans in the United States. It operates through two segments: Insurance and Non-Insurance. It also offers Clover Assistant, a cloud-based software platform, that enables physicians to detect, identify, and manage chronic diseases earlier; and access to data-driven and personalized insights for the patients they treat.